NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

GRI Bio, Inc. (GRI) Stock Analysis

GRI Bio, Inc. (GRI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

GRI

$1.47

+$0.01 (+0.68%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GRI with… →

GRI Key Statistics

As of Oct 21, 2026
Trading
Open
$1.58
Previous Close
$1.46
Day's Range
1.46–1.58
52-Week Range
1.36–64.12
Volume
58.96K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.61
Valuation
Market Cap
$3.21M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−14.71
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$11.96M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.19M
1-Year Return
−97.68%
Dividend and dates
Avg Volume
328.80K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, GRI closed at $1.47, −97.68% over 1 year.

GRI Bio, Inc. (GRI) has a market capitalization of $3.21M.

In fiscal 2025, GRI reported revenue of $0.00.

GRI Stock Return by Calendar Year

GRI Bio, Inc. (GRI) return since Feb 2021: what $10,000 became

1 year
$10,000 $232
−97.68%
5 years
$10,000 $0.002
−99.99998%
Since Feb 2021
$10,000 $0.002
−99.99998%

If you had invested $10,000 in GRI Bio, Inc. (GRI) at the close on February 10, 2021, the earliest close on record here, it would have been worth $0.002 at the close on October 21, 2026: −99.99998% in total, −93.67% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−78.74%
2025−98.25%
2024−97.64%
2023−95.57%
2022−95.15%
2021 (partial year)−20.48%

As of October 21, 2026.

GRI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$11.96M—
2024$0.00−$8.21M—
2023$0.00−$13.04M—
2022$0.00−$3.22M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$11.98M−$11.96M—
2024$0.00—−$8.24M−$8.21M—
2023$0.00—−$11.39M−$13.04M—
2022$0.00—−$2.24M−$3.22M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values GRI Bio, Inc. (GRI) at $3.21M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 3 employees.

GRI last closed at $1.47 on October 21, 2026. That is +$0.01 (+0.68%) against the previous close. Over the past 52 weeks the price has ranged from $1.36 to $64.12. The latest close sits 8.09% above that 52-week low.

Financial Health

In fiscal 2025, GRI Bio, Inc. reported revenue of $0.00. The same year closed with a net loss of $11.96M. Earnings per share on a trailing basis come to −14.71.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at −0.61. Annualized volatility over the trailing 5 years is 171.27%. The trailing one-year total return is −97.68%. Measured over 5 years, that is −95.38% a year compounded.

Growth & Income

The record shows no dividend for GRI.

The strongest complete calendar year on file is 2022 at −95.15%; the weakest is 2025 at −98.25%. Of the 4 complete calendar years on file, 0 finished higher. 2026 is still running; the total return is −78.74% year to date.

Peer Comparison

GRI Bio, Inc. (GRI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
GRI Bio, Inc. GRI $3.21M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. GRI Bio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About GRI Bio, Inc.

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Visit website →